Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Caris Life Sciences, Inc. before investing.

In this article, we go over a few key elements for understanding Caris Life Sciences, Inc.’s stock price such as:

• Caris Life Sciences, Inc.’s current stock price and volume
• Why Caris Life Sciences, Inc.’s stock price changed recently
• Upgrades and downgrades for CAI from analysts
• CAI’s stock price momentum as measured by its relative strength

About Caris Life Sciences, Inc. (CAI)

Before we jump into Caris Life Sciences, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Want to learn more about Caris Life Sciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Caris Life Sciences, Inc..

Caris Life Sciences, Inc.’s Stock Price as of Market Close

As of May 13, 2026, 9:30 AM, CST, Caris Life Sciences, Inc.’s stock price was $16.160.

Caris Life Sciences, Inc. is down 3.58% from its previous closing price of $16.760.

During the last market session, Caris Life Sciences, Inc.’s stock traded between $16.055 and $16.200. Currently, there are approximately 282.56 million shares outstanding for Caris Life Sciences, Inc..

Caris Life Sciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Caris Life Sciences, Inc. Stock Price History

Caris Life Sciences, Inc.’s (CAI) price is currently down 14.95% so far this month.

During the month of May, Caris Life Sciences, Inc.’s stock price has reached a high of $20.030 and a low of $15.700.

Over the last year, Caris Life Sciences, Inc. has hit prices as high as $42.500 and as low as $15.700. Year to date, Caris Life Sciences, Inc.’s stock is down 40.1%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Caris Life Sciences, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of May 12, 2026,, no analysts have changed their rating of Caris Life Sciences, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Caris Life Sciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Caris Life Sciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Caris Life Sciences, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Caris Life Sciences, Inc. (CAI) by visiting AAII Stock Evaluator.

Relative Price Strength of Caris Life Sciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 12, 2026, Caris Life Sciences, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Caris Life Sciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Caris Life Sciences, Inc. Stock Price: Bottom Line

As of May 13, 2026, Caris Life Sciences, Inc.’s stock price is $16.160, which is down 3.58% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Caris Life Sciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.